Trastuzumab emtansine with or without pertuzumab versus trastuzumab with taxane for human epidermal growth factor receptor 2–positive advanced breast cancer: Final results from MARIANNE

帕妥珠单抗 曲妥珠单抗 医学 紫杉烷 曲妥珠单抗 内科学 肿瘤科 多西紫杉醇 乳腺癌 转移性乳腺癌 耐受性 危险系数 癌症 卡培他滨 紫杉醇 人表皮生长因子受体2 化疗 表皮生长因子受体 不利影响 养生 置信区间
作者
Edith A. Perez,Carlos H. Barrios,W. Eiermann,Masakazu Toi,Young Hyuck Im,Pierfranco Conte,Miguel Martín,Tadeusz Pieńkowski,Xavier Pivot,Howard A. Burris,Jennifer Petersen,Sanne de Haas,Silke Hoersch,Monika Patre,Paul Ellis
出处
期刊:Cancer [Wiley]
卷期号:125 (22): 3974-3984 被引量:61
标识
DOI:10.1002/cncr.32392
摘要

In the phase 3 MARIANNE trial, trastuzumab emtansine (T-DM1) with or without pertuzumab showed noninferior progression-free survival and better tolerability than trastuzumab plus a taxane (HT) for the first-line treatment of human epidermal growth factor receptor 2 (HER2)-positive advanced breast cancer. This article reports the final descriptive overall survival (OS) analysis, updated safety data, and additional patient-reported outcomes and biomarker analyses.OS was assessed in 1095 patients with HER2-positive breast cancer and no prior therapy for advanced disease who had been randomized to HT, T-DM1 plus a placebo (hereafter T-DM1), or T-DM1 plus pertuzumab (T-DM1+pertuzumab). A post hoc exploratory landmark analysis of OS, baseline patient and disease characteristics, and tumor biomarkers in patients with and without an objective tumor response (OR) according to the Response Evaluation Criteria in Solid Tumors within 6.5 months of randomization was conducted.The median OS was similar across groups (50.9, 53.7, and 51.8 months for the HT, T-DM1, and T-DM1+pertuzumab groups, respectively). Among patients with an OR, the median OS was longer with T-DM1 (64.4 months) and T-DM1+pertuzumab (not reached) versus HT (56.3 months). No baseline characteristics or biomarkers were strongly associated with OR. The incidence of grade 3 or higher adverse events was greater with HT (55.8%) than T-DM1 (47.1%) or T-DM1+pertuzumab (48.6%). The median time to clinically meaningful deterioration (a 3-point or greater change) in neurotoxicity symptoms was shorter with HT (2.1 months) and T-DM1+pertuzumab (4.2 months) than T-DM1 (6.2 months). Fewer patients reported alopecia and diarrhea and were bothered by treatment side effects in the T-DM1 arm.These results support T-DM1 as a first-line treatment for patients with HER2-positive metastatic breast cancer who are deemed unsuitable for taxane-based therapy.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
PDF的下载单位、IP信息已删除 (2025-6-4)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
田様应助旧梦采纳,获得10
刚刚
mx发布了新的文献求助10
1秒前
寒天抒完成签到 ,获得积分10
2秒前
2秒前
QQ发布了新的文献求助10
3秒前
无情心情完成签到,获得积分10
4秒前
无情心情发布了新的文献求助10
6秒前
老大蒂亚戈应助潇湘雪月采纳,获得10
7秒前
打我呀发布了新的文献求助30
7秒前
8秒前
所所应助科研通管家采纳,获得10
8秒前
汉堡包应助科研通管家采纳,获得10
9秒前
MchemG应助科研通管家采纳,获得10
9秒前
YamDaamCaa应助科研通管家采纳,获得30
9秒前
852应助科研通管家采纳,获得10
9秒前
大模型应助科研通管家采纳,获得30
9秒前
MchemG应助科研通管家采纳,获得10
9秒前
完美世界应助科研通管家采纳,获得30
9秒前
情怀应助科研通管家采纳,获得10
9秒前
科研通AI5应助科研通管家采纳,获得10
9秒前
隐形曼青应助科研通管家采纳,获得10
9秒前
MchemG应助科研通管家采纳,获得10
9秒前
9秒前
李爱国应助深情的雁露采纳,获得10
9秒前
10秒前
盘尼西林发布了新的文献求助10
15秒前
幸福大白发布了新的文献求助10
15秒前
希望天下0贩的0应助李李采纳,获得10
16秒前
QQ完成签到,获得积分20
16秒前
16秒前
BiuBiu怪完成签到,获得积分10
18秒前
Dellamoffy完成签到,获得积分10
18秒前
19秒前
cnlt应助会撒娇的采蓝采纳,获得10
19秒前
海藻发布了新的文献求助10
21秒前
22秒前
盘尼西林完成签到,获得积分10
22秒前
yar应助JK采纳,获得10
24秒前
xxddw发布了新的文献求助10
24秒前
25秒前
高分求助中
A new approach to the extrapolation of accelerated life test data 1000
ACSM’s Guidelines for Exercise Testing and Prescription, 12th edition 500
‘Unruly’ Children: Historical Fieldnotes and Learning Morality in a Taiwan Village (New Departures in Anthropology) 400
Indomethacinのヒトにおける経皮吸収 400
Phylogenetic study of the order Polydesmida (Myriapoda: Diplopoda) 370
基于可调谐半导体激光吸收光谱技术泄漏气体检测系统的研究 350
Robot-supported joining of reinforcement textiles with one-sided sewing heads 320
热门求助领域 (近24小时)
化学 材料科学 医学 生物 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 遗传学 基因 物理化学 催化作用 冶金 细胞生物学 免疫学
热门帖子
关注 科研通微信公众号,转发送积分 3989406
求助须知:如何正确求助?哪些是违规求助? 3531522
关于积分的说明 11254187
捐赠科研通 3270174
什么是DOI,文献DOI怎么找? 1804901
邀请新用户注册赠送积分活动 882105
科研通“疑难数据库(出版商)”最低求助积分说明 809174